1. |
何森, 王斯, 陈晓平. 心房颤动发病机制的研究进展[J]. 华西医学, 2012, 27(5):794-797.
|
2. |
Aronow WS. Etiology, pathophysiology, and treatment of atrial fibrillation:part 1[J]. Cardiol Rev, 2008, 16(4):181-188.
|
3. |
Olshansky B, Rosenfeld LE, Warner AL, et al. The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study:approaches to control rate in atrial fibrillation[J]. J Am Coll Cardiol, 2004, 43(7):1201-1208.
|
4. |
Berisso MZ, Fabbri G, Gonzini L, et al. Antiarrhythmic strategies in patients with atrial fibrillation managed by cardiologists and internists:Antithrombotic Agents in Atrial Fibrillation (ATA-AF) survey[J]. J Cardiovasc Med (Hagerstown), 2014, 15(8):626-635.
|
5. |
Lip GY, Da LE. Stroke prevention in atrial fibrillation:a systematic review[J]. JAMA, 2015, 313(19):1950-1962.
|
6. |
January CT, Wann LS, Alpert JS, et al. College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol, 2014, 64(21):e1-e76.
|
7. |
李树生, 钟强, 杨光田, 等. 静脉应用地尔硫䓬治疗心效观察[J]. 中国急救医学, 1999, 19(7):18-19.
|
8. |
汪维忠. 静注地尔硫䓬治疗肺心病快速型房颤54例疗效观察[J]. 江苏医药, 2004, 30(4):316-317.
|
9. |
李鸣. 地尔硫卓联合地高辛治疗风湿性心脏病并快速型房颤的临床观察[J]. 河南医学研究, 2015, 24(2):124.
|
10. |
Rogenstein C, Kelly AM, Mason S, et al. An international view of how recent-onset atrial fibrillation is treated in the emergency department[J]. Acad Emerg Med, 2012, 19(11):1255-1260.
|
11. |
Kalus JS. Pharmacotherapeutic decision-making for patients with atrial fibrillation[J]. Am J Health Syst Pharm, 2010, 67(9 Suppl 5):S17-S25.
|
12. |
Flaker G, Lopes RD, Hylek E, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation:insights from the Aristotle trial[J]. J Am Coll Cardiol, 2014, 64(15):1541-1550.
|
13. |
Martindale JL, Desouza IS, Silverberg M, et al. β-Blockers versus calcium channel blockers for acute rate control of atrial fibrillation with rapid ventricular response:a systematic review[J]. Eur J Emerg Med, 2015, 22(3):150-154.
|
14. |
Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter:a multicenter study[J]. J Am Coll Cardiol, 1991, 18(4):891-897.
|
15. |
Siu CW, Lau CP, Lee WL, et al. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation[J]. Crit Care Med, 2009, 37(7):2174-2179.
|
16. |
Personett HA, Smoot DL, Stollings JL, et al. Intravenous metoprolol versus diltiazem for rate control in noncardiac, nonthoracic postoperative atrial fibrillation[J]. Ann Pharmacother, 2014, 48(3):314-319.
|
17. |
Demircan C, Cikriklar HI, Engindeniz Z, et al. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation[J]. Emerg Med J, 2005, 22(6):411-414.
|
18. |
Lee J, Kim K, Lee CC, et al. Low-dose diltiazem in atrial fibrillation with rapid ventricular response[J]. Am J Emerg Med, 2011, 29(8):849-854.
|